Non-Adherence to Malaria Chemo-Prophylaxis in Travelers: Mind to the Care Gap!

Background: Travelers are at risk of contracting malaria when moving to endemic areas. Yet, despite effective malaria chemoprophylaxis, imported cases of malaria still occur worldwide. Indeed, some studies have shown a varied adherence level; consequently, a traveler care gap could occur. Methods: A prospective cohort study was carried out in 2017 to evaluate the rate of malaria chemoprophylaxis adherence among Spanish travelers. Results: A post-travel questionnaire was completed by 402 travelers to malaria endemic areas that were prescribed chemoprophylaxis: 67 (16.7%) did not take any dose of chemoprophylaxis and 41 (10.2%) had not even carried it while travelling abroad. The adherence of chemoprophylaxis was 68,7% of travelers, being statistically different according to travel duration, onset of adverse events and type of drug prescribed. The non-adherent travelers reported not continuing with administration mainly because of forgetfulness, fear of side effects and low perceived risk because itinerary changes. Regarding the onset of the medication's secondary adverse events, one in three (35.2%) reported at least one, being more frequent among patients that took mefloquine than atovaquone-proguanil (p=0.01). The main adverse events reported by chemoprophylaxis users were gastrointestinal or sleeping disorders. Conclusions: The suboptimal compliance of chemoprophylaxis is a major lost opportunity to achieve malaria prevention, so it is an important contributor to the traveler care gap